Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
Status:
Completed
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade
osteosarcoma is dismal and unchanged over the last decades. We have already finished a
prospective trial about apatinib for advanced osteosarcoma(NCT02711007) and find it has a
objective response rate of aproximately 45% with median progression-free survival around 5
months. Thus, the investigators explored apatinib activity together with anti-PD1 therapy in
order to induce durable response in patients with relapsed and unresectable osteosarcoma
after the failure of first-line or second-line chemotherapy.
Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine
kinase inhibitor, similar to pazopanib, but with a binding affinity 10 times to VEGFR-2
comparing with pazopanib or sorafenib.
SHR-1210 is a humanized anti-PD-1 monoclonal antibody.